Bloomsburg
Sign InJoin Now
AcquisitionMay 7, 2026Completed
🇺🇸 United States

Catalyst Pharmaceuticals, Inc.Angelini Pharma S.p.A.

Healthcare › Pharmaceuticals

Equity value$4.1BEquity value
View SEC filing Save
AnnouncedMay 7, 2026
ConsiderationCash
StructureOne-step merger
RegionNorth America
Cross-borderYes
Contingent paymentNo

Overview

Angelini Pharma agreed to acquire all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash, about $4.1 billion in equity value, through a merger of an Angelini subsidiary into Catalyst.

Deal rationale

The deal marks Angelini Pharma's entry into the U.S. market and builds a rare disease and brain health platform by combining Catalyst's portfolio and commercial infrastructure with Angelini's expertise.

AI-generated from the SEC filing
CompletedHealthcare › PharmaceuticalsUnited StatesNorth America

Timeline

  1. AnnouncedMay 7, 2026

    Imported from prototype record 276, unverified

    Filing
  2. Regulatory clearanceJun 16, 2026

    HSR waiting period expired or ended.

    Filing
  3. Shareholder vote · ApprovedJul 8, 2026

    Target shareholders approved the deal.

    Filing
  4. ClosedJul 15, 2026

    Closing reported in Form 8-K filed 2026-07-16.

    Filing

Valuation and terms

Equity value$4.1BHeadline figure
Enterprise valueUndisclosed
ConsiderationCash

Advisors

Buy-side
BPBNP ParibasCPCenterview PartnersMSMorgan Stanley
Sell-side
JPJ.P. Morgan

Parties

Target
Catalyst Pharmaceuticals, Inc.
Headquarters
United States
Ticker
CPRX
EDGAR company page
Acquirer
Angelini Pharma S.p.A.
Headquarters
Italy
Ticker
—